DEPENDING on their use, most new drugs must first go through a rigorous system of controlled trials before they can be made available to the general population. For patients who need treatment for specific diseases or conditions, they too must undergo the correct tests in order to identify which drugs are likely to result in the best outcome for them. One Irish company, Diaceutics, is playing a significant role in helping both patients and pharma companies around the world by radically improving patient testing via their realworld data and worldwide laboratory network.
IRISH medtech company Diaceutics was set up in 2005 by Peter Keeling. Based in the Regional Development Centre on the campus of the Institute of Technology in Dundalk, Co Louth and with offices in Belfast and New Jersey in the US, the company employs 55 staff and has an annual turnover of €9m. “We operate in an area known as precision medicine where we work with pharmaceutical companies to help them with patient testing so that patients get the most suitable treatment when they need it,” says Peter. “By improving such patient testing, our work also helps these pharmaceutical companies to accelerate their market penetration and achieve better returns on investment in these new drugs,” he adds.
There has been a revolution in patient testing in recent years. Not long ago all patients with, for example, certain types of cancer, received the exact same treatment.
With better patient testing, doctors are now increasingly able to offer more precise treatment targeted at individual patients. However, while new and better tests are being discovered all the time, many are not getting to the patients who need them because they are either not in the laboratories or they are seen as too costly by the health service provider in that region.
“Diaceutics data illustrates that in cancer, for example, up to 50pc of patients in the developed